基因重组人粒细胞集落刺激因子防治肺癌化疗反应

Recombinant human granulocyte colony stimulating factor in preventing and treating postchemotherapeutic adverse reaction of lung cancer

目的 :探讨国产基因重组人粒细胞集落刺激因子 (rHuG CSF)对肺癌病人化疗所致白细胞减少的防治作用及不良反应。方法 :采用随机分组、自身交叉对比的方法 ,将 6 0例肺癌VIP方案化疗病人分成A ,B两组 (各 30例 ) ,A组第 1周期化疗结束 4 8h开始皮下注射rHuG CSF 3μg·kg- 1,qd ,7～14d ,第 2周期单用化疗 ;B组第 1周期单用化疗 ,第 2周期化疗结束 4 8h开始皮下注射rHuG CSF 3μg·kg- 1,qd ,7～ 14d。自化疗开始隔日查血常规 1次 ,观察白细胞及中性粒细胞的变化。结果 :治疗周期白细胞总数及中性粒细胞最低值均高于对照周期 ,最低值的持续时间和化疗开始至细胞恢复到正常值以上的时间均少于对照周期。骨痛、肌痛和乏力发生率分别为 10 %和 7% ,偶有发热。结论 :rHuG CSF对化疗引起的白细胞减少具有预防和治疗作用 ,不良反应轻微 ,安全可靠。

AIM: To explore the adverse reaction of domestic recombinant human granulocyte colony stimulating factor (rHuG-CSF) and its prevention of leukopenia induced by chemotherapy in patients with lung cancer. METHODS: Sixty patients with lung cancer were divided into A and B groups radomly by self-controll cross over test. In group A, at 48 h after chemotherapy, rHuG-CSF was given 3 μg·kg -1 daily for 7-14 d in the first cycle. And in the second cycle, the patients received chemotherapy alone. In group B, the patients received chemotherapy alone in the first cycle. And at 48 h after chemotherapy, rHuG-CSF was given 3 μg·kg -1 daily for 7-14 d in the second cycle. Blood routine examination was taken every other day from the start of chemotherapy. The changes of leukocyte count and neutrophil count were observed. RESULTS: The numbers of WBC and ANC of the treatment cycle both were higher than those of control. The duration of the nadir of WBC and ANC (WBC<4.0×10 9·L -1,ANC<2.5×10 9·L -1) and the duration from the beginning of chemotherapy to the restoration of WBC and ANC to normal were both less than that of control. The occurence rates of bone pain, myalgia and asthenia were 10 % and 7 %, respectively, fever was infrequent. CONCLUSION: Domestic rHuG-CSF plays an important role in preventing and treating leukopenia and neutropenia induced by chemotherapy. Its adverse reactions were less, so it is safe and reliable.